Project Details
Description
A Phase 2, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosi
| Status | Active |
|---|---|
| Effective start/end date | 4/1/25 → 12/31/32 |
Funding
- NOVARTIS PHARMACEUTICALS CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.